Literature DB >> 26568256

MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.

Pedro Nazareth Aguiar1, Hakaru Tadokoro1, Nora Manoukian Forones2, Ramon Andrade de Mello3,4.   

Abstract

Entities:  

Keywords:  MMR; colorectal cancer; immunotherapy; pembrolizumab

Mesh：

Substances：

Year:  2015        PMID： 26568256     DOI： 10.2217/imt.15.84

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  4 in total

1.  Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Authors:  Brian H Shirts; Eric Q Konnick; Sarah Upham; Tom Walsh; John Michael O Ranola; Angela L Jacobson; Mary-Claire King; Rachel Pearlman; Heather Hampel; Colin C Pritchard
Journal:  Am J Hum Genet       Date:  2018-06-07       Impact factor: 11.025

Review 2.  Dendritic cell-based cancer immunotherapy for colorectal cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Keisuke Saito; Shinichiro Takami; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

3.  Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway.

Authors:  Xinjian Xu; Ji Lv; Fang Guo; Jing Li; Yitao Jia; Da Jiang; Na Wang; Chao Zhang; Lingyu Kong; Yabin Liu; Yanni Zhang; Jian Lv; Zhongxin Li
Journal:  Front Microbiol       Date:  2020-04-30       Impact factor: 5.640

Review 4.  Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.

Authors:  Huang Ao; Zhang Xin; Zhou Jian
Journal:  Biomark Res       Date:  2021-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.